Congratulations to Synucure Therapeutics, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Québec through Investissement Québec as part of the Impulsion PME program.👏
CQDM is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial funding to advance their innovation.
Synucure Therapeutics, specialized in the development of innovative treatments for Parkinson’s disease, is reaching a key milestone to accelerate its research efforts and advance promising therapeutic solutions.
We wish them continued success in the next steps of their development!
📄 Read the full press release 👉https://lnkd.in/eREJWbyv
Congratulations to Synucure Therapeutics on securing $2.8M in funding!
